Citius Oncology, Inc.

$2.54
(as of Jun 23, 11:22 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Citius Oncology, Inc.

Stock Price
$2.54
Ticker Symbol
CTOR
Exchange
NASDAQ

Industry Information for Citius Oncology, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Company Description for Citius Oncology, Inc.

Website
Country
USA
Full Time Employees
0

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Fundamentals for Citius Oncology, Inc.

Market Capitalization
$105,182,032
EBITDA
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.38
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
71,552,400
Percent Owned by Insiders
95.08%
Percent Owned by Institutions
0.76%
52-Week High
52-Week Low

Technical Indicators for Citius Oncology, Inc.

50-Day Moving Average
200-Day Moving Average
RSI
93.19
ATR
0.25

Analyst Ratings for Citius Oncology, Inc.

Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0

News About Citius Oncology, Inc.

Jun 20, 2025, 4:31 PM EST
Investing.com – U.S. stocks were mixed after the close on Friday, as gains in the Oil & Gas, Consumer Goods and Telecoms sectors led shares higher while losses in the Basic Materials, Technology and Healthcare sectors led shares lower. See more.
Jun 9, 2025, 9:10 AM EST
Citius Oncology (NASDAQ:CTOR [https://seekingalpha.com/symbol/CTOR]), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR [https://seekingalpha.com/symbol/CTXR]), has entered into a distribution services agreement with Cardinal Health (NYSE:CAH [https://seekingalpha.com/symbol/CAH]). See more.
Jun 9, 2025, 8:37 AM EST
Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma See more.